Acrobiosystems for English
icon_bulk_orderBulk inquiry/Quick order
0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > BTLA

BTLA

Brief Information

Name:B- and T-lymphocyte attenuator
Target Synonym:BTLA,B- and T-lymphocyte attenuator,B- and T-lymphocyte-associated protein,B And T Lymphocyte Associated,CD272 Antigen,BTLA1,CD272
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:5
Lastest Research Phase:Phase 3 Clinical

Product ListCompare or Buy

ACRO Quality

Synonym Name

BTLA,CD272

Background

B- and T-lymphocyte attenuator (BTLA) is also known as B- and T-lymphocyte-associated protein, CD antigen CD272. BTLA contains one Ig-like V-type (immunoglobulin-like) domain. As a lymphocyte inhibitory receptor, BTLA / CD272 inhibits lymphocytes during immune response. BTLA / CD272 can interact with tyrosine phosphatases PTPN6/SHP-1 and PTPN11/SHP-2, and interact with TNFRSF14/HVEM.

Clinical and Translational Updates

Related Molecule

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
ANB-032 ANB-032 Phase 1 Clinical Anaptysbio Inc Inflammation Details
LY-3361237 LY-3361237 Phase 2 Clinical Eli Lilly And Company, Sanford-Burnham Medical Research Institute Lupus Erythematosus, Systemic; Psoriasis Details
Tifcemalimab TAB-004; JS-004 Phase 2 Clinical Shanghai Junshi Biosciences Co Ltd Solid tumours; Head and Neck Neoplasms; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Nasopharyngeal Carcinoma; Lung Neoplasms; Lymphoma; Neoplasm Metastasis; Melanoma Details

This web search service is supported by Google Inc.

totop
Call us
Call us
North America:
+1 800-810-0816 (Toll Free)
Asia & Pacific:
+86 400-682-2521
Fax
Fax
+1 888-377-6111
Address
Address
1 Innovation Way, Newark, DE 19711, USA

Leave a message